Proof of Concept in Animals for AdaptVac’s breast cancer vaccine candidate published in scientific journal
Hørsholm, Denmark, 28 November 2017 – Today, ExpreS2ion Biotech Holding AB announces that the fully owned subsidiary ExpreS2ion Biotechnologies ApS (“ExpreS2ion”)’s 50% owned joint venture, AdaptVac’s, scientific paper presenting proof of concept in animals (POCA) for its novel breast cancer vaccine candidate, AV001, will be published in the peer reviewed scientific journal ‘OncoImmunology’. The results demonstrate that AV001 is effective for both prevention and therapy of breast cancer in an advanced mouse model.“I am very pleased that the previously announced data demonstrating proof